Anebulo Pharmaceuticals (ANEB) Non-Current Assets (2021 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Non-Current Assets of $148231.0 for Q4 2025, down 66.74% year-over-year from $445731.0 in Q4 2024, and down 10.53% quarter-over-quarter from $165670.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Non-Current Assets (2021 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Non-Current Assets for 4 consecutive years, with $148231.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 66.74% year-over-year to $148231.0; the TTM figure through Dec 2025 stood at $697560.0 (down 67.42% YoY), while the FY2025 annual figure was $183110.0, down 67.6% from the prior year.
- Non-Current Assets slipped to $148231.0 in Q4 2025 per ANEB's latest filing, from $165670.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $684516.0 in Q4 2023 and bottomed at $148231.0 in Q4 2025.
- Historically, Non-Current Assets has averaged $391590.8 across 4 years, with a median of $419230.5 in 2021.
- Annual changes were most pronounced in 2024 — Non-Current Assets sank 34.88% — and 2025, when it plunged 67.9%.
- Anebulo Pharmaceuticals' Non-Current Assets stood at $392730.0 in 2021, then surged by 74.3% to $684516.0 in 2023, then tumbled by 34.88% to $445731.0 in 2024, then sank by 66.74% to $148231.0 in 2025.
- Business Quant data shows ANEB's Non-Current Assets at $148231.0 in Q4 2025, $165670.0 in Q3 2025, and $183110.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 148,231.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 148,231.00 |
| Sep 30, 2025 | 165,670.00 |
| Jun 30, 2025 | 183,110.00 |
| Mar 31, 2025 | 200,549.00 |
| Dec 31, 2024 | 445,731.00 |
| Sep 30, 2024 | 505,427.00 |
| Jun 30, 2024 | 565,124.00 |
| Mar 31, 2024 | 624,820.00 |
| Dec 31, 2023 | 684,516.00 |
| Mar 31, 2021 | 392,730.00 |